Advertisement

CGRP Inhibitors: A Promising New Class of Drugs for Migraine

Published on: 

This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.

In May, the FDA approved erenumab, the first calcitonin gene-related peptide (CGRP) inhibitor for the prevention of migraine in adults. Since then, 2 other CGRP inhibitors have gained approval, providing a new class of drugs for those who suffer from migraine.

This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss the emerging therapy for the condition, which affects 39 million people in the United States.

Log in to listen to the podcast.

Advertisement

Advertisement
Advertisement